Mental Health Drug Initiatives and Stakeholders Workgroup

In late 2004, the Medicaid Chief Medical Officer, Jeffery Thompson, M.D., convened a broad workgroup of providers, stakeholders, pharmacists and government representatives to begin a series of discussions on preferred drug selections in the area of mental health. Formation of the workgroup followed recent findings of duplicate therapy by the American College of Physicians, American Society of Internal Medicine and the American Psychiatric Association, among others. Based on current research and feedback from health-care stakeholders in Washington, the Medical Assistance Administration is working to refine the hard edits that will guide better utilization of elective serotonic reuptake inhibitors and atypical antipsychotics, as well as other drugs used in treating mental illness.

If you would like to join the workgroup's regular e-mail list, please contact Jonell Blatt.

We want to hear from you! Please send your challenging questions for demonstrating when there is an indication for not using a (therapeutic alternative) preferred drug for a New Start antidepressants. Email us.

Not finding what you need? Email us here. We will help you.

• Oct 06, 2006
• Sept 15, 2006
• Aug 18, 2006
• Aug 04, 2006
• July 21, 2006
• July 7, 2006 Draft
• June16, 2006
• June 2, 2006
• May 5, 2006
• March 17, 2006
• March 3 2006
• January 20, 2006
• November 04, 2005
• October 21, 2005
• September 16, 2005
• August 19, 2005
• July 15, 2005
• June 15, 2005
• June 3, 2005
• May 6, 2005
• April 29, 2005
• April 15, 2005
• April 1, 2005

DSHS/MAA Mental Health drugs initiatives January 2005
Draft workgroup business plan

Missouri Annual Report

For comments or questions regarding the HRSA Pharmacy program, email us